APOE

Polymorphisms

Disease/Phenotype	Coronary heart disease, susceptibility to
DNA Change
A.A. Change	[E2:ARG158CYS] [E3:CYS112 AND ARG158] [E4:CYS112ARG]
Variation Type	substitution
Cases	141 patients (112 men and 29 women)
Controls	109 controls (52 men and 57 women)
Frequency	Allele/Genotype Frequency in cases Frequency in controls OR (95%CI) P-value E2 0,0674 0,0367 p>0,05 E3 0,7979 0,9037 p<0,01 E4 0.1348 0.0596 p<0.02 E2/E2 1 (0,71%) 1 (0,92%) E2/E3 14 (9,93%) 5 (4,59%) E2/E4 3 (2,13%) 1 (0,92%) E3/E3 95 (67,38%) 92 (84,40%) E3/E4 21 (14,89%) 8 (7,34%) E4/E4 7 (4,96%) 2 (1,83%)
Comments	An evident association have been found between coronary heart disease and apo E polymorphism.
Reference	Bennouar N, Allami A, Laraqui A, Azeddoug H, El-Kadiri N, Benkouka F, Bendriss A, Ghannam R, Benomar A, Fellat S, Benomar M.[Apolipoprotein E and angiotensin-converting enzyme gene polymorphisms as risk factors of coronary disease]. Ann Biol Clin (Paris). 2004 May-Jun;62(3):295-304.

Disease/Phenotype	End-stage renal disease (ESRD)
DNA Change
A.A. Change	[E2:ARG158CYS] [E3:CYS112 AND ARG158] [E4:CYS112ARG]
Variation Type	others
Cases	109 end-stage renal disease patients
Controls	97 healthy controls
Frequency	Allele/Genotype Frequency in cases Frequency in controls OR (95%CI) P-value e3 73% 82% 1 e2 3% 6% 0.473 (0.181-1.235) 0.093 e4 24% 12% 0.491 (0.277-0.870) 0.009 E3/E3 48% 67% 1 E2/E3 5% 10% 0.613 (0.197-1.904) 0.285 E2/E4 2% 3% 0.818 (0.132–5.074) 0.600 E3/E4 45% 20% 0.316 (0.166–0.601) <0.001
Reference	Lahrach H, Essiarab F, Timinouni M, Hatim B, El Khayat S, Er-Rachdi L, Jarir J, Kettani A, Ghalim N, Taki H, Lebrazi H, Ramdani B, Saïle R.Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis. Ren Fail. 2014 Nov;36(10):1504-9.

Related informations